BioSante Pharmaceuticals to Present at Upcoming Conferences

  
    
  
  
    
      BioSante Pharmaceuticals (AMEX: BPA) today announced that Stephen M. 
      Simes, president and chief executive officer, will present a corporate 
      overview at three upcoming conferences. The conferences are:
    
    
      
        The Annual Sachs North American Forum for Investing and Partnering in 
        Biotech and Medtech on March 12, 2007 at 11:55 a.m. EDT at the 
        Fairmont Copley Plaza in Boston.
      
      
        The Arch Investment Conference on March 21, 2007 at 1:30 p.m. EDT at 
        the St. Regis Hotel in New York City.
      
      
        The Wall Street Reporter Small-Cap Discovery Conference on March 22, 
        2007 at 9:00 a.m. EDT at the Princeton Club of New York.
      
    
    
      A live audio webcast of BioSante’s 
      presentation at these conferences can be accessed on the internet by 
      visiting www.biosantepharma.com. 
      An archive of these presentations will be available at the same address.
    
    
      About BioSante Pharmaceuticals, Inc.
    
    
      BioSante is developing a pipeline of hormone therapy products to treat 
      both men and women. These hormone therapy products are gel formulations 
      for transdermal administration that deliver bio-identical estradiol and 
      testosterone. BioSante's lead products include Elestrin™ 
      (estradiol gel), developed through FDA approval by BioSante, indicated 
      for the treatment of moderate-to-severe vasomotor symptoms associated 
      with menopause, and LibiGel® 
      (transdermal testosterone gel) in Phase III development for the 
      treatment of female sexual dysfunction (FSD). The current market in the 
      U.S. for estrogen and testosterone products is approximately $2.5 
      billion. The transdermal gel formulations used in the women's gel 
      products are licensed by BioSante from Antares Pharma. The company also 
      is developing its calcium phosphate nanotechnology (CaP) for novel 
      vaccines, including hepatitis B, avian flu and biodefense vaccines for 
      toxins such as anthrax, as well as a system for delivering drugs via 
      alternative routes of administration. Additional information is 
      available online at www.biosantepharma.com.